



FOR IMMEDIATE RELEASE

May 06, 2022

Clinical Validation of the EnteroTracker® Presented at North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting

- Two abstracts at the 2021 NASPGHAN meeting showed excellent correlation between biomarkers found in EnteroTracker® samples and biopsy results in 40 Eosinophilic Esophagitis (EoE) patients
- Results also show biomarkers from EnteroTracker® samples followed disease activity accurately

Results from two multi-center clinical studies [1, 2] offered additional evidence that the EnteroTracker® capsule device provides an easy-to-use, minimally invasive means of sampling luminal content in patients with EoE.

One study, “*Clinical validation of the minimally invasive 1-hr esophageal string test (EST) EoEScore for discriminating active from inactive mucosal inflammation in pediatric eosinophilic esophagitis*,” showed that luminal biomarkers captured using the EnteroTracker® were “...significantly associated with markers of disease severity.”¹

Another study, “*Markers of esophageal inflammation and chronic remodeling captured by the minimally invasive capsule based device provide comprehensive assessment of disease activity in eosinophilic esophagitis*” indicated that the EnteroTracker® is clinically useful to discriminate active -vs- inactive disease and capture biomarkers of esophageal remodeling in children with EoE.²

“These studies validate our technology against the clinical standard of biopsy,” said Dr. Steven Ackerman, Chief Science Officer for EnteroTrack. “Together, they show the clinical value of EnteroTracker® to monitor disease activity and treatment response in EoE.”

Robin Shandas, CEO of EnteroTrack agreed. “These results provide additional evidence that our core technology is on track to become a clinical standard for clinicians looking to monitor their EoE patients,” he stated. “It supports patients and physicians who are looking for an inexpensive and convenient method to more frequently track flareups and allow personalization of treatments, which gives patients more options to manage their disease.”

About EnteroTrack

EnteroTrack develops simple-to-use, minimally invasive technologies to sample gastrointestinal (GI) mucosal content that can be assayed for various biomarkers of disease. The company’s platform technology, the EnteroTracker® is initially being used to support clinical monitoring of Eosinophilic Esophagitis in adults and children without need for sedation, advanced training, or complex procedures.

Clinical studies evaluating the utility of the EnteroTracker® for additional applications including Esophageal Adenocarcinoma, Barrett’s Esophagus, GERD, GI microbiome, food allergy testing, and others are currently underway.

Visit www.enterotrack.com or contact Brookelynn Stillwell (brookelynn.stillwell@enterotrack.com) for more information.

¹Burger C, Menard-Katcher C, Pan X, et al: Markers of esophageal inflammation and chronic remodeling captured by the minimally invasive capsule based device provide comprehensive assessment of disease activity in eosinophilic esophagitis, J. Ped. Gastro. Nutr. 2021; 73 (Suppl. 1):S187-S188, Abstract #276.

²Ackerman et al: Clinical validation of the minimally invasive 1-HR Esophageal String Test (EST) EoEScore for discriminating active from inactive mucosal inflammation in pediatric Eosinophilic Esophagitis, J. Ped. Gastro. Nutr. 2021; 73 (Suppl. 1):S497-S498, Abstract #686.